MarketInOut Stock Screener Log In | Sign Up
 

Pharming Group N.V. ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Pharming Group N.V. ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization795.55 mln
Float70.33 mln
Earnings Date10/27/2026

EPS

0.13
Overpriced

P / E

86.15
Speculative

Piotroski F-Score

7 / 9
Strong

Beneish M-Score

-2.55
Likely reliable

Relative Strength

97 / 100
Top performer

Debt / Equity

0.49
Low leverage

Business Description

Pharming Group N.V. is a Dutch medical company founded in 1988 and based in Leiden, Netherlands, that creates treatments for rare and serious health conditions. Its two main products are RUCONEST, which helps patients manage sudden episodes of hereditary angioedema, and Joenja, a daily pill designed to treat a rare immune system disorder called activated PI3K delta syndrome. The company sells its products across the United States, Europe, and other markets worldwide, and works alongside Novartis under a formal research and licensing partnership.

Key Fundamentals

EPS0.13
P/E86.15
ROE3.24
RPS5.22
ROIC5.53
ROA1.76
Interest Cover2.03
EBITDA, mln37.95
EV / EBITDA21.21
EV / EBIT31.11
Revenue, mln366
EV / Revenue2.20

Quote Details

Last 11.20
Change 0.53 (4.97%)
Open 11.32
Volume 25,784
Turnover 288,781
Average Volume 17,588

Financial Ratios

Pre-Tax Profit Margin4
Leverage Ratio1.82
Current Ratio3.01
Price / Book2.77
Price / Tangible Book5.52
Price / Cash Flow25.69
Price / Free Cash Flow25.29
Debt / Equity0.49
Price / Sales2.06

Financial Strength

Altman Z-Score2.71
Piotroski F-Score 7 / 9
Beneish M-Score-2.55
Price to Intrinsic Value2.01
Price to Graham Number3.38
Short Ratio0.57
Short % of Float0.03

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 19.66% 98 / 100   
1 Month 7.28% 91 / 100   
2 Months -14.57% 27 / 100   
6 Months -32.85% 20 / 100   
1 Year -14.5% 33 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog